Mylan Receives Final FDA Approvals for Generic Versions of Lamictal(R) Tablets and Lamictal(R) CD.
PITTSBURGH, Jan. 28 /PRNewswire-FirstCall/ -- Mylan Inc. today announced that its subsidiaries Mylan Pharmaceuticals Inc. and Genpharm ULC received final approvals from the U.S. Food and Drug Administration (FDA) for their Abbreviated New Drug Applications (ANDAs) for Lamotrigine Tablets. Genpharm also received final FDA approval for its ANDA for...

ProAssurance Receives Regulatory Approvals for Transactions with the PICA Group and Georgia Lawyers Insurance Company.
BIRMINGHAM, Ala., Jan. 28 /PRNewswire-FirstCall/ -- ProAssurance Corporation announced today that all required regulatory approvals have been granted in connection with its proposed sponsored demutualization of the PICA Group (PICA), the nation's leading provider of professional liability to doctors of podiatric medicine. The proposed demutualization is being submitted to...

ITC Great Plains Seeks Federal Approvals to Support Kansas and SPP Transmission Investments.
Filing is next milestone for construction of major Kansas transmission improvements by independent transmission company TOPEKA, Kan., Jan. 15 /PRNewswire-FirstCall/ -- Today ITC Great Plains, LLC (ITC Great Plains) filed an application with the Federal Energy Regulatory Commission (FERC) for the approval of rates that would apply...

Priligy(TM) (Dapoxetine) Receives First Regulatory Approvals for the Treatment of Premature Ejaculation (PE) in Finland and Sweden.
Priligy First Oral Prescription Medication Approved for PE BEERSE, Belgium, February 10 /PRNewswire-FirstCall/ -- Janssen-Cilag EMEA, a division of Janssen Pharmaceutica N. V., announced today that Priligy(TM) (dapoxetine) has received marketing authorisation in Finland and Sweden for the on-demand treatment of premature ejaculation (PE) in men 18-64...

Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009.
Projects lower burn rate for 2009 targeting cashflow break-even by Q4-2009 SEATTLE, Jan. 14 /PRNewswire-FirstCall/ -- In meetings held in association with the JP Morgan Healthcare Conference in San Francisco, Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) reviewed 2009 targeted milestones and 2008 accomplishments. CTI is...

N-Viro Fuel Technology Receives Alternative Energy Status From the U.S. Environmental Protection Agency.
- Qualifies Technology for Renewable Energy Incentives - - Helps Pave Way to State Permit Approvals - TOLEDO, Ohio, Jan. 16 /PRNewswire/ -- N-Viro International Corporation, (BULLETIN BOARD: NVIC) , an environmental and materials operating company that owns patented technologies to convert various types of...

Christopher Colwell to Serve as General Manager at Greektown Casino-Hotel.
DETROIT, Feb. 9 /PRNewswire/ -- Christopher Colwell, a Senior Vice President at The Fine Point Group, will serve as General Manager at Greektown Casino-Hotel, subject to necessary regulatory approvals, officials announced today. As part of The Fine Point Group team of gaming industry veterans recently hired by the property,...

Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings.
- Worldwide Sales Increased 10.1 Percent - - Adjusted EPS Growth of 14.0 Percent (GAAP EPS up 27.3 Percent) - - Delivers Double-Digit Sales Growth in Each Major Global Business in 2008 - - Concludes Successful 2008 with Nine New Major Regulatory Approvals...

Media General Announces Sale of WCWJ in Jacksonville, Fla., to Nexstar Broadcasting.
RICHMOND, Va., Jan. 28 /PRNewswire-FirstCall/ -- Media General, Inc. announced today that it has signed a definitive agreement with Nexstar Broadcasting Group, Inc., under which Nexstar will purchase the assets of Media General's CW television station WCWJ in Jacksonville, Fla. The transaction is subject to regulatory approvals and is...

Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy.
- Vimpat(R) demonstrated greater seizure reduction and improved seizure freedom versus placebo when added to first and second-generation antiepileptic drugs (AEDs) - Phase III study supports recent U.S. FDA and European Commission approvals of Vimpat(R) ATLANTA, Jan. 27 /PRNewswire-FirstCall/ -- The new antiepileptic drug Vimpat(R)...